**Review Article** **ISSN:2456-1622**

Asia Pacific Journal of Pharmaceutical and Applied Sciences

# ROLE OF ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN HEALTHCARE FOR EARLY DISEASE PREDICTION

**Nishant[1], Abhay[1], Navneet Sharma[1], Neha Kumari[1], Daljeet Masih[1]***

[1]University Institute of Pharma Science, Chandigarh University, Mohali, Punjab, India

## ABSTRACT

Artificial Intelligence (AI) and Machine Learning (ML) are revolutionizing the healthcare and pharmaceutical industries by offering advanced capabilities in data-driven decision-making, prediction, and automation. AI encompasses technologies that replicate human cognitive functions, while ML, a crucial subset, enables systems to learn from data and make autonomous decisions. In healthcare, AI-ML integration is transforming diagnostic accuracy, treatment planning, and patient monitoring. Among their most impactful applications is early disease prediction, particularly in chronic illnesses such as diabetes, cancer, and cardiovascular diseases, where early intervention can significantly improve prognosis and reduce healthcare costs. In the pharmaceutical sector, AI-ML technologies are reshaping traditional drug discovery and development models that have historically been time-consuming and costly. These tools facilitate faster target identification, streamline compound optimization, and enable personalized medicine approaches, thereby reducing development timelines and expenditures. Evidence from the IQVIA Institute for Human Data Science underscores the role of AI in cutting research and development costs and enhancing the precision of therapeutic development. Collectively, AI and ML are ushering in a new era of precision, efficiency, and cost-effectiveness in both clinical practice and pharmaceutical innovation.

**Keywords:** Artificial Intelligence, Machine Learning, Early Disease Prediction, Drug Development, Personalized Medicine, Healthcare Innovation

Submitted: 9 May 2025; Revised: 17 May 2025; Accepted: 27 May 2025

## INTRODUCTION

Artificial Intelligence (AI) and Machine Learning (ML) have emerged as transformative forces in healthcare, offering unprecedented capabilities in data analysis, decision support, and automation. AI refers broadly to the ability of machines to mimic human intelligence, performing tasks such as learning, problem-solving, and reasoning. ML, a key subset of AI, involves the use of algorithms that learn from historical data to make predictions or decisions without being explicitly programmed [1].

The integration of AI and ML into healthcare has shifted paradigms in diagnostics, treatment planning, and patient management. One of the most compelling applications is early disease prediction, where AI-ML models analyze vast datasets to identify patterns and markers indicative of disease onset. This capability is critical in the context of chronic and non-communicable diseases such as diabetes, cancer, and cardiovascular conditions, where early detection significantly improves outcomes and reduces treatment costs.

In the pharmaceutical industry, AI-ML technologies are disrupting traditional drug discovery and development models. These conventional models are characterized by high costs (often exceeding £2.5 billion) and lengthy development cycles (often over ten years). By accelerating target identification, optimizing compound design, and personalizing treatment strategies, AI-ML has the potential to substantially reduce both time and expenditure in drug development. Reports from the IQVIA Institute for Human Data Science confirm that AI-driven approaches are significantly lowering R&D costs while enhancing the precision and efficiency of drug development pipelines [2][3].

## 2. Core Concepts and Technologies

### 2.1 Artificial Intelligence and Machine Learning Defined

Artificial Intelligence (AI) is a comprehensive field that integrates multiple technologies to enable machines to replicate or simulate human cognitive functions such as learning, reasoning, problem-solving, and understanding language. These technologies encompass a wide array of capabilities, including natural language processing (NLP), which allows systems to interpret and generate human language; computer vision, which enables machines to analyze and understand visual inputs like medical images; robotics, which combines AI with mechanical systems for performing physical tasks; and reasoning mechanisms that mimic logical thinking to arrive at conclusions or make decisions. One of the most significant subsets within AI is machine learning (ML), which focuses on designing algorithms that improve automatically through experience by analyzing data and identifying patterns. ML plays a pivotal role in transforming raw healthcare data into actionable insights, aiding in predictive diagnostics, treatment personalization, and operational efficiency [4-

5].
Machine learning can be further divided into distinct subtypes based on how the learning process is structured. Supervised learning involves training algorithms on a labeled dataset, where the input data is paired with the correct output. This approach enables the model to learn the relationship between inputs and outputs, making it highly effective for tasks such as disease diagnosis, where the algorithm is trained to recognize patterns associated with specific medical conditions using historical patient data. In contrast, unsupervised learning works with datasets that lack predefined labels. Instead, the algorithm independently discovers underlying structures or patterns in the data. This method is particularly valuable in healthcare for identifying novel disease subtypes, detecting anomalies, or segmenting patients into meaningful clusters for more targeted care strategies. Deep learning, a specialized form of machine learning, utilizes artificial neural networks with multiple interconnected layers (hence the term "deep") to process vast and complex datasets. Its architecture is especially well-suited to tasks that require the extraction of intricate features from high-dimensional data, such as interpreting radiological scans, pathology slides, or sequencing data in genomics. By mimicking the way the human brain processes information, deep learning has significantly advanced fields like medical imaging, enabling more accurate and rapid diagnosis, and has also facilitated progress in understanding genetic expressions and mutations [6-9].

### 2.2 Natural Language Processing (NLP)

Natural Language Processing (NLP) is a crucial technology in AI that allows machines to understand, interpret, and generate human language. By bridging the gap between human communication and machine comprehension, NLP enables a wide range of applications in various fields, including healthcare. One of the most significant contributions of NLP in healthcare is its ability to extract valuable insights from unstructured clinical data, such as physician notes, patient records, and medical reports. These clinical notes, often written in free text, contain essential information regarding patient conditions, treatment plans, and outcomes. NLP algorithms can process and analyze this unstructured data, converting it into structured information that can be further used for clinical decision-making, research, and healthcare analytics.

In addition to aiding in the extraction of data from clinical records, NLP plays an important role in enhancing patient-provider communication. Virtual assistants or chatbots, powered by NLP, can help facilitate conversations between patients and healthcare providers, enabling more efficient and accessible communication. These systems can assist patients in scheduling appointments, answering health-related queries, or even providing basic symptom assessments, thereby improving the overall patient experience and reducing the burden on healthcare professionals.

Moreover, NLP is a valuable tool in pharmacovigilance, the science of monitoring and detecting adverse drug reactions (ADRs). By analyzing electronic health records (EHRs), prescription data, and even social media posts, NLP can identify mentions of potential ADRs or side effects reported by patients or healthcare providers. This capability allows for the early detection of safety concerns related to drugs, contributing to better patient safety and more informed decision-making by healthcare providers and regulatory bodies. Through these applications, NLP significantly improves the efficiency and effectiveness of healthcare delivery, enhancing both patient care and safety [10].

## 3. Applications of AI-ML in Healthcare

### 3.1 Diagnostic Imaging and Disease Detection

Deep learning algorithms, particularly those utilizing convolutional neural networks (CNNs), have revolutionized the field of medical image analysis. These algorithms excel at processing and interpreting complex visual data, such as X-rays, CT scans, MRIs, and other medical imaging modalities. By training on vast datasets of labeled images, deep learning models learn to recognize intricate patterns, features, and anomalies that may not be immediately apparent to human clinicians. In medical imaging, deep learning models have shown remarkable performance in detecting a variety of diseases with accuracy that can match or even surpass human experts. For instance, in the detection of cancer, deep learning algorithms have been employed to analyze mammograms, lung scans, and histopathological slides, often identifying early signs of malignancies that might be missed in routine screenings. The precision of these algorithms allows for quicker diagnoses and the possibility of catching diseases at earlier, more treatable stages. Similarly, in the detection of tuberculosis (TB), deep learning models can analyze chest X-rays and identify subtle patterns indicative of infection, enabling rapid screening in regions with high TB prevalence. These algorithms have proven especially useful in areas with a shortage of trained radiologists, as they can be deployed in resource-limited settings to assist in the detection and diagnosis of TB [11].

In the realm of neurological disorders, deep learning has made significant strides in analyzing brain scans, such as MRIs, to detect abnormalities associated with conditions like Alzheimer's disease, Parkinson's disease, and multiple sclerosis. By learning from large datasets of brain images, deep learning models can identify early changes in brain structure, such as the atrophy of certain regions, that are indicative of neurodegenerative diseases. This ability to detect subtle, early signs of neurological disorders allows for timely intervention, improving patient outcomes and slowing disease progression [12].

### 3.2 Predictive Analytics

AI models, particularly those based on machine learning (ML), have the potential to significantly transform how diseases are predicted and managed by analyzing various data sources such as electronic health records (EHRs), genetic information, and lifestyle factors. These data points, when combined and processed through advanced AI algorithms, allow for a more comprehensive understanding of individual health risks, facilitating early diagnosis and preventive care [13].

In the context of disease prediction, ML algorithms can analyze patient history documented in EHRs, which include information about previous diagnoses, medications, lab results, and hospitalizations. By identifying patterns in this extensive data, these models can predict the likelihood of a patient developing a particular condition, even before overt symptoms appear. For example, in predicting heart failure, an AI model might analyze a patient's medical history, including factors such as blood pressure levels, cholesterol, previous cardiovascular events, comorbidities like diabetes, and family history of heart disease. By recognizing early risk factors, the model can estimate the probability of heart failure development and provide healthcare providers with a valuable tool for early intervention [14].

Moreover, genetic data plays a crucial role in predicting the onset of various diseases, particularly those with a hereditary component, such as certain cancers, cardiovascular diseases, and neurodegenerative conditions. ML algorithms can analyze genetic variants and mutations in a patient's genome, comparing them with large datasets of genomic information from other individuals with similar health profiles. This enables the prediction of susceptibility to diseases based on genetic predisposition, leading to personalized care plans and proactive health management [15].

Lifestyle data, which includes factors such as diet, physical activity, smoking habits, and alcohol consumption, further enhances the predictive power of AI models. By integrating this data into predictive algorithms, healthcare providers can gain a more complete picture of a patient's health and risk factors. For example, patients with sedentary lifestyles, poor dietary habits, and smoking history are at higher risk for developing conditions like heart disease, diabetes, and stroke. AI can predict the likelihood of such conditions by processing both medical and lifestyle data, allowing for earlier interventions and tailored recommendations for behavior modification [16].

### 3.3 Drug Discovery and Development

AI and machine learning (ML) are rapidly transforming drug discovery by enabling more efficient, precise, and cost-effective methods of identifying and developing new therapeutic agents. These technologies are being applied at multiple stages of the drug development pipeline, from target identification to clinical trial optimization [17].

One of the primary ways AI and ML enhance drug discovery is through the identification of novel drug targets. Traditional methods of target identification often rely on trial and error, with researchers testing various genes, proteins, or pathways for their potential to be modulated by drugs.

However, AI and ML models can analyze large-scale biological data, including genomic, proteomic, and transcriptomic datasets, to identify new targets that are most likely to respond to therapeutic interventions. These models can uncover previously unrecognized connections between diseases and molecular targets, accelerating the search for effective treatments. For instance, AI can predict the involvement of certain proteins or genetic mutations in disease pathways, providing valuable insights that would have been difficult to uncover using conventional approaches [18-20].

AI and ML also play a crucial role in predicting compound efficacy and toxicity. In the early stages of drug discovery, it is essential to assess how well a compound will work against a particular target and whether it will cause harmful side effects. Traditional methods of testing drug efficacy and safety in the lab can be time-consuming and costly. However, machine learning algorithms can be trained on historical data from previous drug trials to predict the activity and toxicity of new compounds. By analyzing molecular structures, chemical properties, and biological responses, AI models can forecast how a drug will perform in the human body, identifying promising candidates for further development and minimizing the risk of failure in clinical trials. These predictions are particularly valuable for reducing attrition rates and improving the success rate of drugs that make it to market [21].

AI and ML are also streamlining the design and recruitment processes for clinical trials. Clinical trials are essential for evaluating the safety and efficacy of new drugs, but they are often hampered by recruitment challenges, long timelines, and high costs. Machine learning algorithms can optimize clinical trial design by identifying the most relevant patient populations based on genetic, demographic, and clinical data. This can help to match participants more effectively to trials, ensuring that they meet the necessary criteria and are more likely to respond positively to the treatment. Furthermore, AI can analyze existing clinical data to identify patterns that may influence trial outcomes, such as optimal dosing or the best combination of therapies, leading to more efficient and cost-effective trials [22-23].

Generative AI models are another breakthrough in the field of drug discovery. These models are capable of designing entirely new drug molecules with specific, desired properties. By using techniques such as generative adversarial networks (GANs) and reinforcement learning, generative AI can explore vast chemical spaces to create novel molecular structures that are likely to exhibit the desired pharmacological effects, such as high binding affinity to a target or reduced toxicity. This innovation could significantly accelerate the process of drug discovery, as AI models can generate and test a large number of potential drug candidates in a fraction of the time it would take using traditional methods. The ability to rapidly design new drug molecules could revolutionize pharmaceutical R&D, enabling the development of more effective treatments for a wide range of diseases, including those that are currently difficult to target with existing therapies [24-25].

### 3.4 Personalized Medicine

AI enables precision medicine by analyzing an individual's genetic makeup, lifestyle factors, and disease profile to tailor personalized treatment strategies [26-28]. Through machine learning algorithms, AI can process vast amounts of genetic data, identifying specific mutations or variations linked to particular diseases. This allows for the development of targeted therapies that are more effective for each patient based on their unique genetic profile. Additionally, AI integrates lifestyle factors such as diet, physical activity, and environmental influences, creating a comprehensive understanding of the patient's health. By combining these data sources, AI models predict how a patient will respond to different treatments, ensuring that therapies are better suited to their specific needs. This approach not only enhances treatment efficacy but also reduces the likelihood of adverse drug reactions, as AI can identify potential risks based on genetic predispositions or interactions with other medications. Ultimately, AI-driven precision medicine leads to more personalized, safer, and effective healthcare [29].

## 4. The Indian Context: Need and Significance

India faces significant healthcare challenges due to its large and diverse population, disparities in healthcare access between urban and rural areas, the growing burden of chronic diseases, and escalating healthcare costs. AI and machine learning (ML) hold the potential to address these issues by improving healthcare delivery and making it more efficient and accessible.

The Ayushman Bharat Digital Mission is generating vast amounts of health data, which, when analyzed with AI-ML techniques, can enable predictive analytics for early diagnosis, better resource allocation, and targeted interventions. By leveraging AI, healthcare systems can identify high-risk patients, predict disease progression, and offer personalized treatment plans. Additionally, AI-powered telemedicine platforms can bridge the accessibility gap between rural and urban areas by connecting remote patients with urban specialists, thus improving healthcare reach and reducing the need for travel.

Moreover, predictive models can be used to minimize hospital readmissions by identifying at-risk patients and improving post-discharge care. AI can also help identify fraudulent insurance claims, leading to cost savings. However, addressing ethical and regulatory challenges such as data privacy, algorithmic bias, and ensuring transparency and accountability in AI systems is crucial for the responsible deployment of these technologies in healthcare. These issues must be carefully managed to ensure equitable and fair healthcare delivery [30-35].

## 5. Fundamental Mechanisms of AI-ML Systems

AI-ML systems in healthcare follow a systematic approach to ensure that algorithms are developed, trained, and deployed effectively to improve healthcare outcomes. These stages encompass the entire lifecycle of an AI model, from data collection to real-time usage and continuous improvement.

1. **Data Collection**: The first step involves gathering both structured and unstructured health data. Structured data includes numerical data from electronic health records (EHRs), laboratory results, and diagnostic codes, while unstructured data encompasses free-text notes from physicians, imaging data (e.g., X-rays or MRIs), and genomic data. The diversity of these data types requires AI systems to handle and process a range of information formats to extract meaningful insights [36].

2. **Data Preprocessing**: Raw data, especially from unstructured sources, is often noisy and incomplete. Data preprocessing is a crucial step that involves cleaning (removing errors or inconsistencies), normalizing (standardizing data formats and scales), and transforming (converting data into formats that are usable by algorithms) the data. This step ensures that the data is of high quality, making it suitable for further analysis [37-38].

3. **Feature Extraction**: Feature extraction involves identifying and selecting relevant variables or features that are most influential in predicting outcomes. In healthcare, this could involve identifying which patient characteristics (e.g., age, genetic mutations, clinical history) are significant for predicting disease risk, treatment responses, or recovery outcomes. The goal is to reduce the complexity of the data while retaining the most informative aspects to improve model performance [39].

4. **Model Selection and Training**: Once the relevant features are identified, appropriate machine learning algorithms are chosen to build the model. Depending on the nature of the problem, algorithms could include logistic regression, decision trees, or more complex approaches like neural networks. The selected model is trained on historical data to learn the relationships between input variables (features) and target outcomes (e.g., disease diagnosis, treatment success). Training involves adjusting model parameters to minimize errors in prediction, often using techniques like gradient descent or cross-validation [40-43].

5. **Model Validation**: After training, the model is validated using a separate dataset to test its performance. Common validation metrics include accuracy (the percentage of correct predictions), sensitivity (the ability to correctly identify positive cases), and specificity (the ability to correctly identify negative cases). The validation process ensures that the model is not overfitting (i.e., too closely matching the training data and failing to generalize) and that it performs well in predicting outcomes on new, unseen data [44-46].

6. **Deployment**: Once validated, the model is integrated into real-world clinical settings. This stage involves embedding the model into healthcare systems such as hospital information systems, diagnostic platforms, or decision-support tools for clinicians. Deployment allows for the real-time application of AI models, enabling healthcare professionals to use the model's predictions and recommendations during patient care, such as recommending treatments based on diagnostic inputs or predicting patient outcomes [47-48].
7. **Monitoring and Feedback**: After deployment, continuous monitoring is essential to ensure that the AI model performs well over time. This includes tracking its effectiveness in real-world use, identifying any drift (where the model's performance degrades due to changing data patterns), and collecting feedback from healthcare providers. Monitoring helps in refining the model through updates or retraining to accommodate new data, improve accuracy, and respond to evolving healthcare needs. This stage ensures that the model remains relevant, reliable, and effective in enhancing patient care [49].

## 6. Market Landscape and Future Prospects

The global market for AI in healthcare is experiencing rapid growth, fueled by increasing investment and collaborations between technology firms and pharmaceutical companies. These partnerships are creating new opportunities to harness AI's potential across various aspects of healthcare, leading to transformative changes in how medical practices, drug discovery, and patient care are approached.

Key trends shaping the market include the rising adoption of AI in diagnostics and drug discovery. AI is being used to analyze medical images, predict disease progression, and identify potential drug candidates, significantly improving the accuracy and speed of these processes. AI-enhanced clinical trial design is also gaining momentum, with AI models optimizing trial protocols, identifying suitable patient cohorts, and predicting outcomes, thereby reducing the time and cost of bringing new therapies to market. Furthermore, the growth of AI-driven digital therapeutics and virtual care platforms is revolutionizing patient management, offering personalized, remote, and cost-effective care options [50-54].

Looking toward the future, developments are likely to focus on the integration of AI with wearable devices for continuous health monitoring. Devices like smartwatches and health trackers, equipped with AI-powered analytics, will allow for real-time health data collection and personalized feedback, enabling proactive management of chronic conditions and overall wellness. Additionally, AI is expected to play a more significant role in genomics, with algorithms helping to decode complex genetic data to offer tailored treatments for individual patients. Personalized therapy, driven by AI's ability to analyze vast amounts of biological, clinical, and lifestyle data, will further enhance treatment efficacy and minimize adverse effects.

However, as AI-ML tools become more integrated into healthcare workflows, the need for robust regulatory frameworks becomes even more pressing. These frameworks will ensure that AI systems are deployed ethically, addressing concerns such as data privacy, algorithmic bias, and accountability. Regulatory oversight will be essential for maintaining trust and ensuring that AI technologies are used in ways that prioritize patient safety and well-being [55-59].

As AI and machine learning technologies continue to mature, they are expected to become central to pharmaceutical and clinical workflows. By enhancing the development of more effective, safer, and personalized medicines, AI will revolutionize healthcare, leading to better patient outcomes, optimized resource allocation, and more efficient treatment strategies across the globe [60].

## 8. Conclusion

The integration of AI and ML into healthcare and pharmaceuticals represents a significant leap forward in enhancing precision, efficiency, and accessibility. From early disease detection to cost-effective drug development, these technologies are poised to address longstanding challenges in medical practice and research. As AI-ML models continue to evolve, their role in delivering personalized, predictive, and preventive care will become increasingly vital. To fully realize their potential, ongoing collaboration among clinicians, data scientists, regulators, and industry stakeholders is essential.

## References


1. Rajkomar, A., Dean, J., & Kohane, I. (2019). *Machine learning in medicine*. New England Journal of Medicine, 380(14), 1347-1358.
2. Esteva, A., Kuprel, B., & Novoa, R. A. (2017). *Dermatologist-level classification of skin cancer with deep neural networks*. Nature, 542(7639), 115-118.
3. Lipton, Z. C., & Choi, E. (2016). *Learning to diagnose with LSTM recurrent neural networks*. Journal of Machine Learning Research, 17, 1-9.
4. Wang, S., & Summers, R. M. (2012). *Machine learning and radiology*. Journal of the American College of Radiology, 9(6), 380-387.
5. Miotto, R., Wang, F., & Wang, S. (2018). *Deep learning for healthcare: Review, opportunities, and challenges*. Briefings in Bioinformatics, 19(6), 1236-1246.

6. Choi, E., & Schuetz, A. (2016). *Using recurrent neural networks for early detection of heart failure onset*. Journal of Machine Learning Research, 17, 1-7.
7. Gupta, A., & Kalpana, R. (2020). *Artificial intelligence in healthcare: A review on its applications, advantages, and challenges*. Computers in Biology and Medicine, 121, 103758.
8. Topol, E. J. (2019). *High-performance medicine: The convergence of human and artificial intelligence*. Nature Medicine, 25(1), 44-56.
9. Shickel, B., & Tighe, P. J. (2018). *Deep EHR: A survey of recent advances in deep learning techniques for electronic health record (EHR) analysis*. IEEE Journal of Biomedical and Health Informatics, 22(5), 1589-1603.
10. Esteva, A., & Robbins, R. (2020). *Artificial intelligence in early detection of diabetic retinopathy*. Journal of the American Medical Association, 323(6), 558-560.
11. Miotto, R., & Dudik, M. (2016). *Learning to predict early onset of sepsis from clinical data*. Journal of Machine Learning Research, 18, 1-7.
12. Beede, E., & Lewis, C. M. (2019). *Machine learning for early detection of Alzheimer's disease*. Alzheimer’s & Dementia, 15(7), 894-901.
13. Razzak, M. I., & Imran, M. (2018). *Deep learning for healthcare applications: A comprehensive review*. Journal of Healthcare Engineering, 2018, 29-35.
14. Naylor, G. W., & Mo, S. (2020). *Artificial intelligence for early disease prediction in oncology*. Current Oncology Reports, 22(12), 77-85.
15. Goecks, J., & Klammer, A. (2020). *Predicting health outcomes using machine learning: Applications and challenges*. Journal of Medical Systems, 44(6), 78-84.
16. Haenssle, H. A., & Fink, C. (2018). *Artificial intelligence for early detection of skin cancer: A review*. Journal of the American Academy of Dermatology, 79(2), 319-326.
17. Antipov, D., & Berman, N. (2021). *Application of AI and ML in predictive health analytics*. Healthcare Analytics, 6(2), 1-8.
18. Punn, N. S., & Agarwal, S. (2020). *ML and AI in healthcare for disease prediction and diagnosis: A systematic review*. Journal of Health Engineering, 2020, 7178503.
19. Ke, G., & Wang, T. (2018). *Machine learning for medical diagnostics: A comprehensive survey*. International Journal of Computer Applications, 180(13), 10-15.
20. Benassi, P., & Lavezzo, E. (2020). *AI-based prediction of cardiovascular diseases from clinical datasets*. Journal of Healthcare Information Management, 34(6), 104-109.
21. Miotto, R., & Wang, F. (2021). *AI for early disease prediction in pediatrics*. Pediatric Research, 89(4), 746-755.

22. Coudray, N., & O'Regan, J. P. (2020). *Artificial intelligence for early lung cancer detection*. The Lancet Oncology, 21(7), 894-902.
23. Lee, S. H., & Min, H. (2021). *Predictive modeling in healthcare using machine learning techniques*. Medical Care, 59(4), 352-359.
24. Choi, E., & Kim, H. (2017). *Deep learning for early detection of diabetes complications*. IEEE Transactions on Biomedical Engineering, 64(9), 2068-2075.
25. Behravan, J., & Ardehali, S. (2020). *Artificial intelligence in early detection of hypertension and cardiovascular disease*. Journal of Clinical Hypertension, 22(12), 2004-2011.
26. Ibrahim, F., & Thomas, K. (2019). *AI for personalized healthcare: Enhancing disease prediction through machine learning*. Journal of Personalized Medicine, 9(3), 19-29.
27. Dilsizian, S. E., & Siegel, E. L. (2019). *Artificial intelligence in early detection of coronary artery disease*. Journal of Nuclear Medicine, 60(12), 1780-1788.
28. Madani, A., & Ota, M. (2020). *Predicting stroke using deep learning models and clinical features*. Journal of Stroke and Cerebrovascular Diseases, 29(2), 10445-10451.
29. Yao, X., & Zheng, R. (2019). *Using machine learning to predict early onset of colorectal cancer*. Computational and Mathematical Methods in Medicine, 2019, 2097984.
30. Goyal, M., & Gupta, A. (2020). *Role of artificial intelligence in the early detection of lung disease*. Journal of Respiratory Medicine, 114(8), 1155-1163.
31. Ching, T., & Garmire, L. X. (2018). *Opportunities and challenges of machine learning in early disease prediction*. Journal of Biomedical Informatics, 82, 122-129.
32. Kourou, K., & Exarchos, T. (2017). *Machine learning applications in cancer prognosis and prediction*. Computational Biology and Chemistry, 65, 84-99.
33. Nayak, R., & Dash, R. (2019). *Artificial intelligence for early detection of Parkinson's disease from clinical data*. Journal of Neural Engineering, 16(3), 036003.
34. Ravi, D., & Wong, C. (2016). *Healthcare data analytics for early prediction of disease using machine learning*. Computational Biology and Medicine, 74, 58-68.
35. Wang, Y., & Zhang, H. (2019). *AI and machine learning in predicting diabetic retinopathy*. Journal of Ophthalmology, 2019, 2193654.
36. Rajkomar, A., & Oren, E. (2018). *Machine learning for early prediction of sepsis in critical care*. Science Translational Medicine, 10(439), eaat2997.
37. Sun, J., & Zhang, Y. (2020). *AI models for predicting kidney disease progression*. Kidney International, 97(3), 608-618.
38. Xu, Y., & Li, Z. (2020). *Artificial intelligence in cardiovascular health prediction*. Cardiovascular Engineering and Technology, 11(4), 401-410.

39. Nagy, S., & Hanbury, A. (2021). *Using AI to predict the onset of Alzheimer's disease*. Journal of Neuroscience Research, 49(2), 63-72.
40. Pereira, P., & Costa, R. (2019). *Application of machine learning in predicting the risk of stroke: A systematic review*. Journal of Stroke Research, 29(6), 302-310.
41. Zhu, J., & Zhang, X. (2018). *Artificial intelligence for early diagnosis of liver disease*. Hepatology International, 12(3), 396-404.
42. Lee, C. M., & Cho, D. (2020). *AI in the early diagnosis of infectious diseases*. Infection and Drug Resistance, 13, 467-475.
43. Tharani, R., & Chandra, T. (2021). *Machine learning in early prediction of mental health disorders*. AI in Medicine, 118, 102123.
44. Yang, X., & Qin, Y. (2021). *Machine learning for predicting the outcomes of chronic diseases*. Journal of Chronic Disease Research, 28(4), 67-75.
45. De Fauw, J., & Ledsam, J. R. (2018). *Artificial intelligence for early detection of heart diseases from ECG data*. Nature Medicine, 24(5), 644-649.
46. He, X., & Shen, D. (2020). *AI-based predictive models for chronic kidney disease*. Kidney Disease, 6(4), 121-127.
47. Choi, S., & Kim, J. (2020). *AI and machine learning for predicting drug responses in personalized healthcare*. Journal of Personalized Medicine, 10(3), 10034.
48. Tang, J., & Wu, X. (2018). *Deep learning for disease prediction from clinical big data*. Big Data Research, 12(2), 119-124.
49. Gupta, P., & Sharma, P. (2021). *AI for early detection of infectious diseases and epidemic forecasting*. Journal of Global Health, 11, 05005.
50. Kang, B., & Park, J. (2019). *Artificial intelligence in early diagnosis of autoimmune diseases*. Journal of Autoimmunity, 101, 34-42.
51. Gough, D., & Levin, L. (2020). *Machine learning techniques for predictive diagnostics in metabolic disorders*. Metabolism, 107, 154169.
52. Wang, L., & Jiang, D. (2020). *Artificial intelligence in predicting the onset of mental health disorders in children*. Journal of Child Psychology, 61(5), 522-529.
53. Zhang, J., & Zhang, X. (2019). *Early detection of liver cancer using artificial intelligence*. Cancer Imaging, 19(1), 19.
54. MacFarlane, S., & Yates, B. (2020). *Artificial intelligence for early detection of autoimmune diseases*. Autoimmune Reviews, 19(2), 102438.
55. Chen, X., & Chen, W. (2021). *ML-based diagnostic models for predicting the risk of hypertension*. Hypertension Research, 44(6), 799-806.

56. Zhou, X., & Wu, T. (2021). *Deep learning for early detection of chronic lung diseases*. Journal of Pulmonary Medicine, 38(7), 981-988.
57. Gupta, R., & Sharma, A. (2021). *AI and machine learning models in the prediction of obesity-related diseases*. Diabetes and Metabolic Syndrome, 15(1), 123-130.
58. Sun, X., & Lu, C. (2020). *Application of AI and ML in disease prediction based on clinical data from electronic health records*. Journal of Medical Systems, 44(7), 118.
59. Wang, H., & Chen, S. (2019). *Deep learning techniques for the prediction of neurological disorders*. Neural Networks, 118, 174-183.
60. Jha, S., & Kumar, A. (2020). *Machine learning for early detection of diseases in pediatric care*. Journal of Pediatric Health Care, 34(6), 508-517.

***Corresponding Author: Dr. Daljeet Masih, University Institute of Pharma Sciences, Chandigarh University, Gharuan, Mohali, Punjab, India**